KPV after the October 28 policy: oral and topical only, and injectable KPV isn't covered

What changed on October 28

KPV is one of six peptides in HHS's October 28, 2026 enforcement discretion policy. Starting October 30, HHS says it does not intend to act against covered compounders that make KPV acetate in topical or oral forms under the policy's conditions.

FDA's advisory committee recommended KPV for the 503A Bulks List on July 23, 2026, 8 to 6 with one abstention. It was nominated for wound healing and inflammatory conditions.

The policy's other conditions apply to every one of the six peptides: the ingredient must come from an FDA-registered facility with a valid certificate of analysis made under CGMP, the product may contain only one active ingredient, the only delivery device allowed is an FDA 510(k)-cleared syringe, the label must say it is a compounded drug not for resale, and serious adverse events must be reported to FDA MedWatch.

What it didn't change

It did not approve the peptide; compounded drugs are not FDA approved. It did not add it to the 503A Bulks List, which still requires formal rulemaking. It does not cover "research use only" vials, blends with other peptides, or any route the policy doesn't list. HHS calls the policy interim and says it can revisit it; public comments are open through November 13, 2026.

For KPV, two limits matter most: no injectable KPV, and oral products must come with documentation that the specific formula is adequately absorbed in people.

What KPV is, and what the evidence says

KPV is a three-amino-acid fragment (lysine-proline-valine) of alpha-MSH, a hormone involved in inflammation. Interest comes from lab and animal studies, especially in models of gut inflammation and skin.

Human evidence is scarce, and data on how much oral or topical KPV the body actually absorbs is lacking. Claims about healing the gut or clearing skin conditions in people are not established.

Who should slow down

Anyone with inflammatory bowel disease or a skin condition already under treatment should talk to their clinician before adding anything. Anyone pregnant or breastfeeding. Athletes in tested sport should check the WADA list.

Ask any provider: Is a licensed clinician reviewing my case? Which state-licensed 503A pharmacy fills it? Is there a certificate of analysis for the ingredient? Is it this peptide alone, with no blend? Is the route one the policy covers? What's the full price, including refills, and how do I cancel? If anything says "FDA approved," treat that as a red flag.